---
created: 2025-04-13
updated: 2025-04-13T10:52
id: zsVTSqZv<L
specialty: hemato
specialty_id: 148
tags:
  - source/ak-original-decks::step-1::zanki-pharmacology
  - "source/ak-step1-v11:": 
  - theme/b&b::11-hematology::01-hemostasis::07-anticoagulants
  - "source/ak-step1-v11:": 
  - theme/firstaid::10-hematology-oncology::05-pharm::03-warfarin
  - "source/ak-step1-v11:": 
  - source/ome-banner::basic-science::13-hematology-oncology::11-hemostasis
  - "source/ak-step1-v11:": 
  - theme/physeo::09-pharm::17-hem/onc-pharm::warfarin
  - "source/ak-step1-v11:": 
  - theme/pixorize::03-pharm::10-heme::warfarin
  - "source/ak-step1-v11:": 
  - theme/sketchypharm::03-blood-&-inflammation::01-anticoagulants-&-thrombolytics::02-warfarin
  - source/ak-step1-v11::^other::^highyield::1-highyield
  - source/ak-step2-v11::!shelf::im::no-dupes
  - "source/ak-step2-v11:": 
  - theme/resources-by-rotation::im::uw::heme/onc::heme/onc-zanki
  - source/ak-step2-v11::original-decks::zanki-step-2::im::hemeonc"
type: flashcard
---

# Question
The anti-coagulants **protein C** and **S** are reduced early in warfarin therapy, leading to a(n) **hyper**-coagulable state

---

# Answer
protein C and S have shorter half-lives than factors II, VII, IX, and X